Type 2 diabetes mellitus

Type 2 diabetes mellitus
IntDiabetesFed · Public domain · source
Name	Type 2 diabetes mellitus
Field	Endocrinology
Symptoms	Hyperglycemia, polyuria, polydipsia
Complications	Cardiovascular disease, nephropathy, retinopathy, neuropathy
Onset	Adult, increasingly in adolescents
Duration	Chronic
Causes	Insulin resistance, beta cell dysfunction
Risks	Obesity, family history
Diagnosis	Blood glucose testing, HbA1c
Treatment	Lifestyle modification, pharmacotherapy, surgery

Type 2 diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia due to insulin resistance and progressive pancreatic beta cell dysfunction. It commonly presents in adults but has become more prevalent among adolescents and young adults, and it is associated with major comorbidities that drive morbidity and mortality worldwide.

Signs and symptoms

Patients may report increased urination, excessive thirst, unexplained weight change, fatigue, blurred vision, and recurrent infections; acute presentations include hyperosmolar hyperglycemic state. These clinical features overlap with presentations seen in World Health Organization guidelines, cases managed at Mayo Clinic, and descriptions in curricula at institutions such as Harvard Medical School, Johns Hopkins Hospital, and Cleveland Clinic. Physical findings often include central adiposity, acanthosis nigricans noted in dermatology texts from Massachusetts General Hospital and cardiometabolic assessments referenced by American Diabetes Association panels. Symptoms may be subtle and first recognized during screenings in programs run by Centers for Disease Control and Prevention, National Health Service (England), and community clinics supported by Bill & Melinda Gates Foundation initiatives.

Pathophysiology and risk factors

The pathophysiology involves peripheral insulin resistance, hepatic glucose overproduction, and declining beta cell mass/function described in landmark research from Eli Lilly and Company and academic centers like University of Cambridge and Stanford University. Key risk factors include obesity, sedentary lifestyle, aging, and genetic predisposition documented in cohorts from Framingham Heart Study, Nurses' Health Study, and UK Biobank. Ethnicity-specific risks are emphasized in reports from World Health Organization and studies in populations from India, China, United States, Mexico, and Brazil. Metabolic contributors—dyslipidemia, hypertension, and chronic inflammation—were detailed in consensus statements by American Heart Association and European Society of Cardiology, while environmental and socioeconomic drivers have been analyzed by researchers at Harvard T.H. Chan School of Public Health and London School of Hygiene & Tropical Medicine.

Diagnosis

Diagnosis relies on laboratory measurements endorsed by panels at American Diabetes Association, World Health Organization, and diagnostic workgroups convened at International Diabetes Federation meetings. Criteria include fasting plasma glucose, 2-hour oral glucose tolerance testing, and glycated hemoglobin (HbA1c) thresholds used in protocols from Centers for Disease Control and Prevention, National Institutes of Health, and national ministries of health such as Ministry of Health and Family Welfare (India). Point-of-care testing performed in settings like Kaiser Permanente and community programs at Johns Hopkins Bloomberg School of Public Health support case finding. Differential diagnosis requires exclusion of type 1 diabetes described in pediatrics literature from Great Ormond Street Hospital and monogenic forms outlined by teams at Mayo Clinic Laboratories.

Prevention and screening

Primary prevention strategies follow randomized trials such as those coordinated by Diabetes Prevention Program investigators and translational work at University of California, San Francisco showing lifestyle modification reduces progression. Public health screening strategies are recommended by World Health Organization, Centers for Disease Control and Prevention, and national agencies like National Health Service (England) and Health Canada, with risk-based screening in high-prevalence groups identified in studies from China CDC and Indian Council of Medical Research. Community interventions have been implemented by organizations including American Diabetes Association, World Bank, and non-governmental partners like Partners In Health. Policy measures on food environments and urban planning have been advocated by experts at United Nations forums and research centers such as University College London.

Management and treatment

Management uses a stepped approach combining lifestyle interventions, pharmacotherapy, and sometimes bariatric surgery. Lifestyle programs informed by trials from Diabetes Prevention Program and translational models at Yale School of Medicine emphasize diet, physical activity, and weight loss. First-line pharmacotherapy with metformin follows guidelines from American Diabetes Association and clinical trials sponsored by pharmaceutical companies including AstraZeneca and Merck & Co., while additional agents—GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, insulin—are supported by trial networks at European Association for the Study of Diabetes, National Institute for Health and Care Excellence, and research centers such as Massachusetts General Hospital. Bariatric procedures performed at centers like Cleveland Clinic and Johns Hopkins Hospital are considered for eligible patients with severe obesity. Multidisciplinary care models involve endocrinology clinics at Mayo Clinic, diabetes education programs from Joslin Diabetes Center, and telemedicine platforms developed by Teladoc Health and academic partners at Stanford Health Care.

Complications

Macrovascular complications include coronary artery disease, stroke, and peripheral arterial disease discussed in guidelines from American Heart Association, European Society of Cardiology, and surgical series from Mayo Clinic. Microvascular complications—retinopathy, nephropathy, and neuropathy—are detailed in publications from American Academy of Ophthalmology, National Kidney Foundation, and neurology departments at Johns Hopkins University. Prevention and management of complications are priorities in programs run by World Health Organization, International Diabetes Federation, and philanthropic partners such as Wellcome Trust.

Epidemiology and public health impact

Global prevalence has risen sharply with demographically driven increases documented by World Health Organization and epidemiological analyses in Global Burden of Disease Study coordinated by Institute for Health Metrics and Evaluation. Large national surveys from Centers for Disease Control and Prevention, Public Health England, Indian Council of Medical Research, and China CDC document regional burdens and disparities. Economic and health system impacts have been evaluated by Organisation for Economic Co-operation and Development and policy analyses at World Bank, influencing priority-setting at ministries such as Department of Health and Human Services (United States) and Ministry of Health (Brazil). Research consortia at Wellcome Trust Sanger Institute and networks like Translational Medicine Consortium continue to study prevention, treatment, and outcomes.

Category:Endocrine disorders